Mountain Valley MD Advances Quicksome™ Sublingual Delivery Platform for Compounded Peptide Applications, Reports on Initial Formulation Work Across Multiple Peptides Including BPC-157

Key Takeaways

• Quicksome™ platform tested on BPC‑157, GHK‑Cu, KPV, SNAP‑8, retatrutide
• Sublingual delivery aims to replace injections and cold‑chain logistics
• Peptide therapeutics market projected to reach $295 B by 2033
• Regulatory review could reclassify 14 peptides, expanding compounded market
• MVMD seeks licensing and partnership deals across North and South America

Pulse Analysis

The Quicksome™ technology tackles a long‑standing obstacle in peptide therapy: poor oral bioavailability. By dissolving a tablet under the tongue, the platform bypasses stomach acid and proteolytic enzymes, delivering the active molecule directly into the bloodstream. Early formulation work on five peptides shows the system can maintain stability at room temperature, potentially eliminating the need for refrigeration and needle‑based administration—a clear advantage for both patients and supply chains.

Peptide therapeutics are on a rapid growth trajectory, with market estimates climbing from roughly $141 billion in 2025 to $295 billion by 2033, an 8.7% CAGR. High‑profile GLP‑1 agents already generated about $46 billion in 2024 revenue, and next‑generation candidates like retatrutide could add $15‑30 billion by 2031. Simultaneously, U.S. regulators are reconsidering the classification of dozens of peptides, which could dramatically expand the compounded‑pharmacy market. MVMD’s timing aligns with this regulatory momentum, positioning its delivery platform as a ready‑to‑deploy solution for a broader range of compounds.

Rather than pursuing traditional drug development, MVMD is building a licensing and partnership engine across North and South America. By offering Quicksome™ as a platform technology, the company can embed its formulation into existing compounded‑pharmacy networks, telehealth services, and wellness brands without bearing the costs of clinical trials. This model promises faster market entry, diversified revenue streams, and the ability to capture value from multiple peptide categories, making it a compelling play for investors watching the evolving peptide landscape.